Description

Oncimmune Holdings plc specializes in creating and bringing to market advanced diagnostic technologies for cancer, serving regions across the United Kingdom, North America, Europe, and globally. A cornerstone product is EarlyCDT-Lung, an immunodiagnostic test specifically designed for the detection and identification of lung cancer. The company further advances its capabilities with SeroTag, a robust platform dedicated to discovering and validating biomarkers vital for patient stratification across numerous cancer types, infectious ailments, and a range of autoimmune disorders. Additionally, they provide NavigAID, a bespoke panel for disease characterization. Founded in 2015, Oncimmune Holdings plc operates from its base in Nottingham, UK.